RT Journal Article
T1 Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study.
A1 Alcala-Diaz, Juan F
A1 Limia-Perez, Laura
A1 Gomez-Huelgas, Ricardo
A1 Martin-Escalante, Maria D
A1 Cortes-Rodriguez, Begoña
A1 Zambrana-Garcia, Jose L
A1 Entrenas-Castillo, Marta
A1 Perez-Caballero, Ana I
A1 Lopez-Carmona, Maria D
A1 Garcia-Alegria, Javier
A1 Lozano-Rodriguez-Mancheño, Aquiles
A1 Arenas-de Larriva, Maria Del Sol
A1 Perez-Belmonte, Luis M
A1 Jungreis, Irwin
A1 Bouillon, Roger
A1 Quesada-Gomez, Jose Manual
A1 Lopez-Miranda, Jose
K1 COVID-19
K1 COVID-19 drug treatment
K1 SARS-CoV-2
K1 Calcifediol
K1 Vitamin D
AB Calcifediol has been proposed as a potential treatment for COVID-19 patients. To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Retrospective, multicenter, open, non-randomized cohort study. Hospitalized care. Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain. Patients received calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not. In-hospital mortality during the first 30 days after admission. A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; p  7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure  Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings.
PB MDPI
YR 2021
FD 2021-05-21
LK http://hdl.handle.net/10668/17870
UL http://hdl.handle.net/10668/17870
LA en
NO Alcala-Diaz JF, Limia-Perez L, Gomez-Huelgas R, Martin-Escalante MD, Cortes-Rodriguez B, Zambrana-Garcia JL, et al. Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study. Nutrients. 2021 May 21;13(6):1760
NO Financed by public funds through the CLINICAL RESEARCH PROGRAM IN COVID-19 OF ANDALUSIA (COVID-0011-2020), Fundación Progreso y Salud, Consejería de Salud y Familias (Junta de Andalucía).
DS RISalud
RD Apr 6, 2025